Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles

Simşek, Soner; Eroğlu, Hakan; Kürüm, Barış; Ulubayram, Kezban

doi:10.3109/02652048.2012.692400

Cited by 49 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[396] Amphiphilic NPs, however, have been found to be effective at prolonging circulation time and improving brain drug delivery in vivo without causing significant toxic effects (Figure 38). [449,497,498] Figure 38. Schematic illustration of the structure of an amphiphilic NP self-assembled from its constituent polymers.…”

Section: Diphtheria Toxin Receptor (Dt R )mentioning

confidence: 99%

Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases

et al. 2018

View full text Add to dashboard Cite

Therapies directed toward the central nervous system remain difficult to translate into improved clinical outcomes. This is largely due to the blood-brain barrier (BBB), arguably the most tightly regulated interface in the human body, which routinely excludes most therapeutics. Advances in the engineering of nanomaterials and their application in biomedicine (i.e., nanomedicine) are enabling new strategies that have the potential to help improve our understanding and treatment of neurological diseases. Herein, the various mechanisms by which therapeutics can be delivered to the brain are examined and key challenges facing translation of this research from benchtop to bedside are highlighted. Following a contextual overview of the BBB anatomy and physiology in both healthy and diseased states, relevant therapeutic strategies for bypassing and crossing the BBB are discussed. The focus here is especially on nanomaterial-based drug delivery systems and the potential of these to overcome the biological challenges imposed by the BBB. Finally, disease-targeting strategies and clearance mechanisms are explored. The objective is to provide the diverse range of researchers active in the field (e.g., material scientists, chemists, engineers, neuroscientists, and clinicians) with an easily accessible guide to the key opportunities and challenges currently facing the nanomaterial-mediated treatment of neurological diseases.

show abstract

Section: Diphtheria Toxin Receptor (Dt R )mentioning

confidence: 99%

Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We used dichloromethane (DCM) and chloroform because of the slight miscibility with water and therefore micro droplets were obtained. Poly (lactic-co-glycolic acid)-poly ethylene glycol (PLGA-b-PEG) diblock copolymer was used as the polymeric material, since it is widely used in biomaterials research because of its biocompatible and biodegradable properties [23][24][25] . In addition, once the porous PLGA-b-PEG construct is obtained, it preserves its structural integrity without any need for second crosslinking step.…”

Section: Introductionmentioning

confidence: 99%

Honeycomb-like PLGA-b-PEG Structure Creation with T-Junction Microdroplets

Gultekinoglu¹,

Jiang

Bayram³

et al. 2018

Langmuir

Self Cite

View full text Add to dashboard Cite

Amphiphilic block copolymers are widely used in science owing to their versatile properties. In this study, amphiphilic block copolymer poly(lactic- co-glycolic acid)- block-poly(ethylene glycol) (PLGA- b-PEG) was used to create microdroplets in a T-junction microfluidic device with a well-defined geometry. To compare interfacial characteristics of microdroplets, dichloromethane (DCM) and chloroform were used to prepare PLGA- b-PEG solution as an oil phase. In the T-junction device, water and oil phases were manipulated at variable flow rates from 50 to 300 μL/min by increments of 50 μL/min. Fabricated microdroplets were directly collected on a glass slide. After a drying period, porous two-dimensional and three-dimensional structures were obtained as honeycomb-like structure. Pore sizes were increased according to increased water/oil flow rate for both DCM and chloroform solutions. Also, it was shown that increasing polymer concentration decreased the pore size of honeycomb-like structures at a constant water/oil flow rate (50:50 μL/min). Additionally, PLGA- b-PEG nanoparticles were also obtained on the struts of honeycomb-like structures according to the water solubility, volatility, and viscosity properties of oil phases, by the aid of Marangoni flow. The resulting structures have a great potential to be used in biomedical applications, especially in drug delivery-related studies, with nanoparticle forming ability and cellular responses in different surface morphologies.

show abstract

“…Furthermore, PEGylation is still the most widely used strategy method because a strategy cannot be used to enhance the circulation half-life of all kinds of NPs in the blood cells (Huang et al, 2016). It was stated that the PEG layer around the NPs reduced the adsorption of opsonins and other serum proteins could be reduced by the presence of PEG on the surface of NPs (Vannucci et al, 2012, Xin et al, 2012, Simsek et al, 2013). Here we found that the unmodified Qdots which carry PEG amine on its surface showed a high accumulation in the liver, which cannot explain the long circulation time of the formulated Qdots-VAP because VAP binds to the SSTR2 expressed in blood cells (Bhathena and Recant, 1980, Perez et al, 2003, Lichtenauer-Kaligis et al, 2004, Petrak, 2005, Reynaert et al, 2007, ter Veld et al, 2007, Muscarella et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide

Abdellatif

Abou-Taleb

Ghany

et al. 2018

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Cancer may be difficult to target, however, if cancer targeted this provides the chance for a better and more effective treatment. Quantum dots (Qdots) coated vapreotide (VAP) as a somatostatin receptors (SSTRs) agonist can be efficient targeting issue since may reduce side effects and increase drug delivery to the target tissue. This study highlights the active targeting of cancer cells by cells imaging with improving the therapeutic outcomes. VAP was conjugated to Qdots using amine-to-sulfhydryl crosslinker. The synthesized Qdots-VAP was characterized by determination of size, measuring the zeta-potential and UV fluorometer. The cellular uptake was studied using different cell lines. Finally, the Qdots-VAP was injected into a rat model. The results showed a size of 479.8 ± 15 and 604.88 ± 17 nm for unmodified Qdots and Qdots-VAP respectively, while the zeta potential of particles went from negative to positive charge which proved the conjugation of VAP to Qdots. The fluorometer recorded a redshift for Qdots-VAP compared with unmodified Qdots. Moreover, cellular uptake exhibited high specific binding with cells which express SSTRs using confocal microscopy and flow cytometry (17.3 MFU comparing to 3.1 MFU of control, P < 0.001). Finally, an in vivo study showed a strong accumulation of Qdots-VAP in the blood cells (70%). In conclusion, Qdots-VAP can play a crucial role in cancer diagnosis and treatment of blood cells diseases when conjugated with VAP as SSTRs agonist.

show abstract

Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles

Cited by 49 publications

References 41 publications

Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases

Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases

Honeycomb-like PLGA-b-PEG Structure Creation with T-Junction Microdroplets

Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide

Contact Info

Product

Resources

About